>>
Home > Clinical Trials > Clinical Trials at Vhio

CLINICAL TRIALS

CLINICAL TRIALS AT VHIO

Clinical trials compare current state-of-the-art treatment with a potentially superior treatment and may even offer new treatment options and drugs to patients for whom there are no alternatives. 

Patients at the Vall d’Hebron University Hospital’s Oncology Department are therefore considered as potential candidates for inclusion in our clinical trials . Although all patients may not be eligible or do not agree to take part in a clinical trial, we offer this option to all who meet the necessary criteria as per the different research protocols.

As a highly established reference in cancer treatment we continue to witness continued, annual growth in the number of patients starting a new treatment in clinical trials as well as number of trials conducted (see figure 1 and figure 2).


 Figure  1: Annual recruitment of patients enrolled in Clinical Trials (Phases I- II - III)

  1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Included in phase I 35 59 57 110 130 120 108 132 139 171 222 245 277 290 345 303 370
Included in phase II 59 72 66 94 91 130 73 165 170 133 161 207 180 253 257 302 327
Included in phase III 95 128 175 109 84 129 111 85 143 180 189 221 218 236 241 166 282
Nº of patients included 189 259 298 313 305 379 292 382 452 484 572 673 675 779 843 771 979


 Figure 2: Annual Distribution of Phase I, II and III Trials

  1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Phase I trials 6 10 12 14 17 15 16 19 20 26 31 37 48 66 75 83 106
Phase II trials 19 22 23 23 22 19 30 32 42 40 55 54 57 85 96 99 94
Phase III trials 14 17 22 25 18 20 21 21 31 37 45 49 56 68 61 64 89
Nº of clinical trials 39 49 57 62 57 54 67 72 93 103 131 140 161 219 232 246 289


Driving drug development & targeted therapies against cancer, the Clinical Trials Office,  the Research Unit for Molecular Therapy of Cancer - "la Caixa" in collaboration with many other oncology professionals including Molecular Pathologists, Radiologists and Interventional Radiologists well as many other specialists at Vall d´Hebron (Dermatologists, Cardiologists, Ophthalmologists), along with the research carried out by the Early Clinical Drug Development Groups and other VHIO Groups, have collectively established VHIO as a leading reference in drug discovery from concept to clinic. 

To find out more about our Clinical Trials Office, the Research Unit for Molecular Therapy of Cancer - "la Caixa", our Clinical Research Oncology Nurses, and Pharmacy Unit please see: